|
1
|
Clinical guidelines: ways ahead.
|
J Eval Clin Pract
|
1998
|
4.56
|
|
2
|
Data protection legislation: interpretation and barriers to research.
|
BMJ
|
2000
|
4.43
|
|
3
|
The Iranian health insurance system; past experiences, present challenges and future strategies.
|
Iran J Public Health
|
2012
|
3.28
|
|
4
|
Same information, different decisions: the influence of evidence on the management of hypertension in the elderly.
|
Br J Gen Pract
|
1996
|
3.15
|
|
5
|
Alterations in prescribing by general practitioner fundholders: an observational study.
|
BMJ
|
1995
|
2.96
|
|
6
|
Why do GPs not implement evidence-based guidelines? A descriptive study.
|
Fam Pract
|
2001
|
2.94
|
|
7
|
The risk of cardiovascular disease in hypertensive patients.
|
Br J Gen Pract
|
1997
|
2.11
|
|
8
|
Involving consumers in a needs-led research programme: a pilot project.
|
Health Expect
|
2001
|
2.10
|
|
9
|
Therapeutic conservatism.
|
J R Coll Physicians Lond
|
1993
|
2.02
|
|
10
|
Pharmacoeconomics: evaluating the evaluators.
|
Br J Clin Pharmacol
|
1997
|
1.89
|
|
11
|
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
|
QJM
|
2003
|
1.55
|
|
12
|
Lifestyle medicines.
|
BMJ
|
2000
|
1.50
|
|
13
|
Economic evaluation under managed competition: evidence from the U.K.
|
Soc Sci Med
|
1997
|
1.48
|
|
14
|
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
|
Health Technol Assess
|
2003
|
1.46
|
|
15
|
Clinical guidelines: development, implementation, and effectiveness.
|
Postgrad Med J
|
1995
|
1.43
|
|
16
|
A randomized trial of Evidence-based OutReach (EBOR): rationale and design.
|
Control Clin Trials
|
1999
|
1.42
|
|
17
|
Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
|
Thorax
|
1999
|
1.42
|
|
18
|
The impact of health economics on healthcare delivery: the health economists' perspective.
|
Pharmacoeconomics
|
2001
|
1.39
|
|
19
|
Therapeutic conservatism.
|
J R Coll Physicians Lond
|
1993
|
1.39
|
|
20
|
The management of hypertension in the elderly by general practitioners in Merseyside: the rule of halves revisited.
|
Br J Gen Pract
|
1998
|
1.39
|
|
21
|
Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics.
|
Pharmacoeconomics
|
1996
|
1.39
|
|
22
|
Health care financing in iran; is privatization a good solution?
|
Iran J Public Health
|
2012
|
1.38
|
|
23
|
Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study.
|
BMJ
|
1996
|
1.37
|
|
24
|
Prescribing costs in general practice fundholding.
|
Lancet
|
1996
|
1.27
|
|
25
|
Generic prescribing: time to regulate the market? Price rises are a blow to nascent primary care groups.
|
BMJ
|
2000
|
1.26
|
|
26
|
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
|
Health Technol Assess
|
2004
|
1.26
|
|
27
|
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
|
Health Technol Assess
|
2007
|
1.19
|
|
28
|
Coronary artery stents: a rapid systematic review and economic evaluation.
|
Health Technol Assess
|
2004
|
1.18
|
|
29
|
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.
|
Health Econ
|
2001
|
1.16
|
|
30
|
Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers.
|
Br J Clin Pharmacol
|
1991
|
1.14
|
|
31
|
Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders.
|
Br J Gen Pract
|
1999
|
1.13
|
|
32
|
Drug-eluting stents: a systematic review and economic evaluation.
|
Health Technol Assess
|
2007
|
1.10
|
|
33
|
Addressing barriers to change: an RCT of practice-based education to improve the management of hypertension in the elderly.
|
Br J Gen Pract
|
1999
|
1.10
|
|
34
|
Clinical guidelines-the hidden costs.
|
BMJ
|
1999
|
1.09
|
|
35
|
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
|
Health Technol Assess
|
2011
|
1.08
|
|
36
|
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
|
Pharmacogenomics J
|
2010
|
1.07
|
|
37
|
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.
|
Heart
|
2005
|
1.06
|
|
38
|
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.
|
Health Technol Assess
|
2008
|
1.06
|
|
39
|
The UK indicative prescribing scheme: background and operation.
|
Pharmacoeconomics
|
1992
|
1.03
|
|
40
|
Lack of an interaction between propranolol and sumatriptan.
|
Br J Clin Pharmacol
|
1991
|
1.02
|
|
41
|
Pharmacoeconomics: integrating economic evaluation into clinical trials.
|
Br J Clin Pharmacol
|
1997
|
0.99
|
|
42
|
Supply and regulation of medicines.
|
BMJ
|
2005
|
0.94
|
|
43
|
FHSA medical advisers: friends or foes?
|
BMJ
|
1992
|
0.94
|
|
44
|
The management of Pneumocystis carinii pneumonia.
|
Br J Clin Pharmacol
|
1999
|
0.93
|
|
45
|
Medication errors in primary care in Riyadh City, Saudi Arabia.
|
East Mediterr Health J
|
2011
|
0.93
|
|
46
|
Risk sharing and payment by results.
|
Clin Pharmacol Ther
|
2008
|
0.92
|
|
47
|
Medicines regulation and health technology assessment.
|
Clin Pharmacol Ther
|
2010
|
0.92
|
|
48
|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
|
Health Technol Assess
|
2009
|
0.91
|
|
49
|
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes.
|
Cochrane Database Syst Rev
|
2005
|
0.88
|
|
50
|
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
|
Health Technol Assess
|
2006
|
0.88
|
|
51
|
Accounting for noncompliance in pharmacoeconomic evaluations.
|
Pharmacoeconomics
|
2001
|
0.88
|
|
52
|
Integrating clinical pharmacology in a new problem based medical undergraduate curriculum.
|
Br J Clin Pharmacol
|
1997
|
0.88
|
|
53
|
Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels.
|
Diabetologia
|
2006
|
0.88
|
|
54
|
Reporting of adverse drug reactions: practice in the UK.
|
Nurs Times
|
1998
|
0.87
|
|
55
|
Determinants of physicians' medication prescribing behaviour in primary care in Riyadh City, Saudi Arabia.
|
East Mediterr Health J
|
2011
|
0.85
|
|
56
|
Selective serotonin reuptake inhibitors.
|
BMJ
|
1992
|
0.85
|
|
57
|
Physicians medication prescribing in primary care in Riyadh City, Saudi Arabia. Literature review, part 1: variations in drug prescribing.
|
East Mediterr Health J
|
2011
|
0.85
|
|
58
|
A UK national prescribing list?
|
Pharmacoeconomics
|
1995
|
0.83
|
|
59
|
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
|
Cochrane Database Syst Rev
|
2007
|
0.83
|
|
60
|
Local clinical guidelines: description and evaluation of a participative method for their development and implementation.
|
Fam Pract
|
1996
|
0.83
|
|
61
|
Prescribing at the interface between primary and secondary care in the UK. Towards joint formularies?
|
Pharmacoeconomics
|
1999
|
0.83
|
|
62
|
Hypertension in the elderly: attitudes of British patients and general practitioners.
|
J Hum Hypertens
|
1998
|
0.82
|
|
63
|
Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
|
Pharmacoeconomics
|
2001
|
0.82
|
|
64
|
Prescription charges: change overdue? Britain can learn from systems of copayments based on drugs' effectiveness.
|
BMJ
|
1998
|
0.82
|
|
65
|
Interaction of metoprolol and fluoxetine.
|
Lancet
|
1993
|
0.81
|
|
66
|
Early access to new medicines.
|
Clin Pharmacol Ther
|
2008
|
0.81
|
|
67
|
Review article: current treatment and optimal patient management in pancreatic cancer.
|
Aliment Pharmacol Ther
|
1998
|
0.81
|
|
68
|
Auditing the management of hypertension in British general practice: a critical literature review.
|
Br J Gen Pract
|
1998
|
0.81
|
|
69
|
Predictors of quality of medication prescribing in primary care in Riyadh City, Saudi Arabia.
|
East Mediterr Health J
|
2011
|
0.80
|
|
70
|
Erlotinib for the treatment of relapsed non-small cell lung cancer.
|
Health Technol Assess
|
2009
|
0.80
|
|
71
|
The association of some practice characteristics with antibiotic prescribing.
|
Pharmacoepidemiol Drug Saf
|
1999
|
0.80
|
|
72
|
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
|
Health Technol Assess
|
2010
|
0.79
|
|
73
|
The influence of practice characteristics on the prescribing of benzodiazepines and appetite suppressant drugs.
|
Pharmacoepidemiol Drug Saf
|
1998
|
0.79
|
|
74
|
Loperamide related toxic megacolon in Clostridium difficile colitis.
|
Postgrad Med J
|
1990
|
0.79
|
|
75
|
Physicians' medication prescribing in primary care . in Riyadh City, Saudi Arabia. Literature review, part 3: prescribing errors.
|
East Mediterr Health J
|
2011
|
0.78
|
|
76
|
Physicians' medication prescribing in primary care in Riyadh City, Saudi Arabia. Literature review, part 2: rational prescribing.
|
East Mediterr Health J
|
2011
|
0.78
|
|
77
|
[Medication prescribing pattern in primary care in Riyadh City, Saudi Arabia]
|
East Mediterr Health J
|
2011
|
0.78
|
|
78
|
Haemodynamic responses in young and elderly, healthy subjects during ambient and warm head-up tilt.
|
Clin Sci (Lond)
|
1998
|
0.78
|
|
79
|
Comparing hypertension guidelines. Technical difficulties may have affected study's results.
|
BMJ
|
1996
|
0.77
|
|
80
|
Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings.
|
Pharmacoeconomics
|
1998
|
0.77
|
|
81
|
Benefit of statins in daily practice? A six-year retrospective observational study.
|
Pharmacol Res
|
2009
|
0.77
|
|
82
|
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
|
Health Technol Assess
|
2007
|
0.77
|
|
83
|
Effectiveness of three interventions on primary care physicians' medication prescribing in Riyadh City, Saudi Arabia.
|
East Mediterr Health J
|
2011
|
0.77
|
|
84
|
Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer.
|
Aliment Pharmacol Ther
|
1998
|
0.76
|
|
85
|
Availability of medicines in the European Union: results from the EURO-Medicines project.
|
Eur J Clin Pharmacol
|
2001
|
0.76
|
|
86
|
Therapeutic conservatism.
|
J R Coll Physicians Lond
|
1994
|
0.75
|
|
87
|
"Slurry lung": a report of three cases.
|
Thorax
|
1991
|
0.75
|
|
88
|
Feasibility study of multicentre comparison of NHS hospital pharmacy computer data.
|
Br J Clin Pharmacol
|
2000
|
0.75
|
|
89
|
Upper gastrointestinal endoscopy.
|
BMJ
|
1995
|
0.75
|
|
90
|
ACE inhibitors and peripheral vascular disease.
|
Lancet
|
1990
|
0.75
|
|
91
|
Importance of health economics must be recognised when trials are designed.
|
BMJ
|
1999
|
0.75
|
|
92
|
How evidence is reviewed.
|
Occas Pap R Coll Gen Pract
|
2001
|
0.75
|
|
93
|
Generic substitution.
|
J R Coll Physicians Lond
|
1993
|
0.75
|
|
94
|
Treatment of gastro-oesophageal reflux disease in adults. "Step down" strategy of treatment would be expensive.
|
BMJ
|
1999
|
0.75
|
|
95
|
The future of health research in the UK.
|
Lancet
|
2006
|
0.75
|
|
96
|
Cost effectiveness of lowering cholesterol. Study did not take account of confounders.
|
BMJ
|
1996
|
0.75
|
|
97
|
Effects of fundholding on prescribing habits. Results of similar study in Mersey were different.
|
BMJ
|
1996
|
0.75
|
|
98
|
Topical NSAIDs are better than placebo. Safety, efficacy, and therapeutic role of nsaids must be clarified.
|
BMJ
|
1998
|
0.75
|
|
99
|
Impedance cardiography.
|
Br J Clin Pharmacol
|
1993
|
0.75
|
|
100
|
Metipranolol-induced adverse reactions: I. The rechallenge study.
|
Eye (Lond)
|
1992
|
0.75
|
|
101
|
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
|
Health Technol Assess
|
2009
|
0.75
|
|
102
|
Commercialisation of disease management.
|
Lancet
|
1996
|
0.75
|
|
103
|
An alternative to body mass index for standardizing body weight for stature.
|
QJM
|
2000
|
0.75
|
|
104
|
Effective contracting of high-tech health care for patients at home.
|
J Manag Med
|
1996
|
0.75
|
|
105
|
Donepezil and Alzheimer's dementia.
|
Clin Perform Qual Health Care
|
2000
|
0.75
|
|
106
|
The clinical and scientific basis of drug toxicity. A report of a conference.
|
J R Coll Physicians Lond
|
1990
|
0.75
|
|
107
|
Trends in primary care antibiotic prescribing in England 1994-1998.
|
Pharmacoepidemiol Drug Saf
|
2001
|
0.75
|
|
108
|
Contracting for high-tech health care for patients at home: a survey of purchaser responses.
|
J Manag Med
|
1996
|
0.75
|
|
109
|
Different vasodilating mechanisms--different peripheral effects?
|
J Cardiovasc Pharmacol
|
1992
|
0.75
|
|
110
|
'This house believes that pharmacoeconomic analysis should be mandated by governments rather than left to market forces'.
|
Pharmacoeconomics
|
1994
|
0.75
|
|
111
|
Autoregulation of tissue blood flow in essential hypertension.
|
Hypertension
|
1986
|
0.75
|
|
112
|
Patient packs and the prescribing of antimicrobial agents.
|
J Antimicrob Chemother
|
1996
|
0.75
|
|
113
|
General practice fundholders' prescribing savings in one region of the United Kingdom, 1991-1994.
|
Health Policy
|
1997
|
0.75
|
|
114
|
Managing the entry of new medicines in the National Health Service: health authority experiences and prospects for primary care groups and trusts.
|
Health Soc Care Community
|
2001
|
0.75
|
|
115
|
Digest of evidence ... pramipexole and Parkinson's disease.
|
Clin Perform Qual Health Care
|
2000
|
0.75
|
|
116
|
Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions.
|
Lancet
|
1995
|
0.75
|